Experimental HCV Drugs
Experimental HCV Drugs
CROI 2014: Hepatitis C Treatment in the Real World [VIDEO]
- Details
- Category: HCV Treatment
- Published on Monday, 03 March 2014 00:00
- Written by Gregory Fowler
The opening day of the 21st Conference on Rtroviruses and Opportuistic Infections (CROI 2014) featured a press conference on advances in the treatment of hepatitis C, with a focus on how new drugs may be used in the real world, given barriers such as high cost and a shortage of experienced medical providers.
CROI 2014: Retrovirus Conference Starts Monday in Boston
- Details
- Category: HIV Treatment
- Published on Friday, 28 February 2014 00:00
- Written by HIVandHepatitis.com
The 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) will take place next week, March 3-6, at the Hynes Convention Center in Boston. HIVandHepatitis.com will be on site all week to bring you the latest news coverage about HIV, hepatitis C, and related topics.
Daclatasvir + Asunaprevir Works Well for HCV 1b, but 1a Requires Interferon
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 20 February 2014 00:00
- Written by Liz Highleyman
An all-oral combination of Bristol-Myers Squibb's daclatasvir plus asunaprevir cured nearly 80% of patients with genotype 1b hepatitis C virus (HCV), but people with harder-to-treat HCV subtype 1a needed to add pegylated interferon and ribavirin to achieve high sustained response rates, researchers reported in the March 2014 Journal of Hepatology.
Daclatasvir and Asunaprevir Designated as Hepatitis C "Breakthrough" Therapy
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 28 February 2014 00:00
- Written by Bristol-Myers Squibb
Bristol-Myers Squibb's dual regimen containing the hepatitis C virus NS5A inhibitor daclatasvir plus the HCV protease inhibitor asunaprevir has been granted "breakthrough therapy" status by the U.S. Food and Drug Administration, putting in on track for rapid approval, the company announced this week.
Gilead 4-Drug Hepatitis C Combo Shows Modest Efficacy in Phase 2 Trial
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 14 February 2014 00:00
- Written by Liz Highleyman
An interferon-free regimen containing 3 direct-acting antiviral drugs plus ribavirin cured about 60% of genotype 1 hepatitis C patients treated with the highest dose for 24 weeks, according to study findings reported in the February 5 advance edition of Hepatology -- only a modest cure rate compared with some other new regimens with cure rates approaching 100%.
Web Design and Development by